Kessler Topaz Meltzer Check Investigates uniQure N.V. Shareholder Losses

Investigation of uniQure N.V. by Kessler Topaz Meltzer & Check LLP

Kessler Topaz Meltzer & Check, LLP, a prominent law firm, is currently conducting an investigation concerning possible violations of federal securities laws affecting investors of uniQure N.V. (NASDAQ: QURE). This legal inquiry is particularly pertinent following a substantial drop in uniQure’s share price, which resulted from the company’s public announcements regarding its investigational gene therapy, AMT-130, aimed at treating Huntington's disease.

On November 3, 2025, uniQure disclosed that the FDA had determined that data provided by the company regarding its AMT-130 did not offer adequate evidence to support its Biologics License Application (BLA) submission. The acknowledgment raised concerns over the reliability of the Phase I/II clinical trial data, which was previously considered potentially suitable for the BLA process. The company subsequently indicated that the filing timeline for the BLA was uncertain.

Following this announcement, uniQure’s stock plummeted, with shares falling over 50% from a closing price of $67.69 on October 31 to $34.29 by November 3. Such a drastic decline may have resulted in substantial losses for investors, prompting Kessler Topaz Meltzer & Check to step in and assist those affected.

The firm is eager to hear from shareholders who might have suffered significant losses due to this turn of events. They are encouraging individuals who invested in uniQure to contact them for potential legal action aimed at recovering losses incurred as a result of this stock drop.

Kessler Topaz Meltzer & Check provides a platform for investors to fill out an online form to learn more about the ongoing investigation. This law firm specializes in prosecuting class action lawsuits related to securities fraud and other breaches of fiduciary duties, striving to uphold corporate governance and protect investor interests. With a history of recovering billions on behalf of investors both in the United States and globally, they continue to lead the charge for reform in corporate accountability.

Potential clients or concerned investors are encouraged to reach out to Kessler Topaz Meltzer & Check, noting that the firm has maintained a robust commitment to transparency and clients' rights. Those interested can contact Jonathan Naji, Esq. at their Radnor, PA office by calling (484) 270-1453 or via email at email protected]. More information is also accessible on their official website at [www.ktmc.com.

In conclusion, as the investigation unfolds, uniQure investors should remain vigilant. The implications of the FDA's stance on AMT-130 not only affect the company’s financials but also set a precedent for handling clinical trial submissions in the complex landscape of gene therapy approvals. Investors grappling with uncertainty in the wake of this announcement are urged to seek legal guidance promptly to explore their options and understand their rights in what is undoubtedly a challenging situation.